Develops RNAi therapeutics for rare genetic diseases.
Dec 2025Revenue $3.71B/yrExpenses $3.21B/yr
Reached break-even Aug 2025
Figures by year
When did Alnylam Pharmaceuticals become profitable?
Its revenue passed its expenses in Aug 2025. In the 12 months to Dec 2025, revenue was $3.71B and expenses $3.21B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $3.71B | $3.21B | $502M |
| Dec 2024 | $2.25B | $2.43B | −$177M |
| Dec 2023 | $1.83B | $2.11B | −$282M |
| Dec 2022 | $1.04B | $1.82B | −$785M |
| Dec 2021 | $844M | $1.55B | −$709M |
| Dec 2020 | $493M | $1.32B | −$828M |
| Dec 2019 | $220M | $1.16B | −$939M |
| Dec 2018 | $74.9M | $890M | −$815M |
| Dec 2017 | $89.9M | $590M | −$500M |
| Dec 2016 | $47.2M | $472M | −$425M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.